ACE2 and COVID-19: Favipiravir-treated patients were found to have a higher clinical recovery rate and more effectively reduced incidence of fever and cough (Chen C. et al., 2020) which manifested as mild and moderate symptoms of COVID-19 where during this initial stage, SARS-CoV-2 multiplies and binds to angiotensin-converting enzyme 2 (ACE2) receptor on human cells (Siddiqi and Mehra, 2020; Wan et al., 2020).